Reported results
- Research and development expenses were $17.9 million in the third quarter of 2026, consistent with $17.9 million in the prior-year quarter.
- General and administrative expenses were $7.8 million in the third quarter of 2026, compared to $10.3 million for the prior-year quarter.
- Net loss was $24.4 million for the third quarter of 2026, compared to $26.3 million for the prior-year quarter.
- Net loss per share - basic and diluted was $0.39 for the three months ended September 30, 2026, compared to $0.43 for the three months ended September 30, 2025.
- Cash, cash equivalents and short-term investments were $142.6 million as of September 30, 2026.
Guidance
- The Company expects its cash, cash equivalents and short-term investments of $142.6 million as of September 30, 2026 to be sufficient to fund operations to mid-2028.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
